



4 April 2023

Upgraded revenue and earnings guidance

Blis Technologies (NZX:BLT) announced today that it has upgraded its revenue and earnings guidance for the financial year ended 31 March 2023.

The company expects full year revenue of around \$10.1m and EBITDA deficit of between \$0.6m to \$0.7m, subject to completion of audit and year end adjustments.

Guidance provided in February was for revenue between \$9.5m and \$9.8m and EBITDA deficit in the range of \$1.0m to \$1.2m.

“The upgraded guidance reflects increased sales activity and lower than expected costs of exiting the Canadian retail market.”

“We have been pleased with the improvement in performance of the company delivered by the strategy reset, revenue growth and returning to a positive EBITDA in the second half of the year.” said CEO Brian Watson.

Results for the 12 months to 31 March 2023 are expected to be announced in late May.

Ends

For further information, please contact:

Brian Watson
CEO
+64 27 705 9133

About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics

Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.

Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics